ACLX Insider Trading

Insider Ownership Percentage: 8.35%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $15,774,879.05

Arcellx Insider Trading History Chart

This chart shows the insider buying and selling history at Arcellx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3-$50M$0$50MTotal Insider BuyingTotal Insider Selling

Arcellx Share Price & Price History

Current Price: $68.98
Price Change: Price Increase of +0.12 (0.17%)
As of 07/11/2025 05:00 PM ET

This chart shows the closing price history over time for ACLX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
AugSepOctNovDecJanFebMarAprMayJunJul$68.98Closing price on 07/12/25:

SEC Filings (Institutional Ownership Changes) for Arcellx (NASDAQ:ACLX)

96.03% of Arcellx stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ACLX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$130kbought$34ksoldQ3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3-$500M$0$500MTotal InflowsTotal Outflows
Arcellx logo
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Read More on Arcellx

Today's Range

Now: $68.98
Low: $67.70
High: $69.48

50 Day Range

MA: $63.50
Low: $52.77
High: $69.00

52 Week Range

Now: $68.98
Low: $47.86
High: $107.37

Volume

293,426 shs

Average Volume

608,152 shs

Market Capitalization

$3.80 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.28

Who are the company insiders with the largest holdings of Arcellx?

Arcellx's top insider investors include:
  1. Jill Carroll (Director)
  2. Rami Elghandour (Insider)
  3. Christopher Heery (Insider)
  4. Michelle Gilson (CFO)
  5. Kavita Patel (Director)
  6. Olivia C Ware (Director)
Learn More about top insider investors at Arcellx.

Who are the major institutional investors of Arcellx?

Arcellx's top institutional shareholders include:
  1. Harbor Capital Advisors Inc. — 0.04%
  2. High Net Worth Advisory Group LLC — 0.01%
Learn More about top institutional investors of Arcellx stock.

Which institutional investors are selling Arcellx stock?

During the previous quarter, ACLX stock was sold by these institutional investors:
  1. High Net Worth Advisory Group LLC
Within the previous year, company insiders that have sold Arcellx company stock include:
  1. Jill Carroll (Director)
  2. Rami Elghandour (Insider)
  3. Christopher Heery (Insider)
  4. Michelle Gilson (CFO)
Learn More investors selling Arcellx stock.

Which institutional investors are buying Arcellx stock?

Within the previous quarter, ACLX stock was acquired by institutional investors including:
  1. Harbor Capital Advisors Inc.